Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs

Journal of Microbiology and Biotechnology

Volumn 18, Issue 6, 2008, Pages 1179-1185

  Kang, Mi Lan ^a   Kang, Sang Gyun ^a   Jiang, Hu Lin ^b   Guo, Ding Ding ^b   Lee, Deog Yong ^a   Rayamahji, Nabin ^a   Seo, Yeon Soo ^a   Cho, Chong Su ^b   Yoo, Han Sang ^a  

^a Seoul National University   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Atrophic rhinitis; Bordetella bronchiseptica; Chitosan microspheres; Intranasal administration; Pigs

Indexed keywords

BACTERIAL TOXIN; BACTERIAL VACCINE; BORDETELLA BRONCHISEPTICA VACCINE; CHITOSAN; DERMONECROTOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROSPHERE; UNCLASSIFIED DRUG; BACTERIUM ANTIBODY; BORDETELLA VIRULENCE FACTOR; DERMONECROTIC TOXIN, BORDETELLA; DRUG CARRIER; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACTERIUM ISOLATION; BORDETELLA BRONCHISEPTICA; CONTROLLED STUDY; GELATION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOSTIMULATION; MORPHOLOGY; NONHUMAN; NOSE MUCOSA; PORCINE ATROPHIC RHINITIS; ANIMAL; ANIMAL DISEASE; ATROPHIC RHINITIS; BACTERIAL INFECTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOLOGY; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; MUCOSAL IMMUNITY; SWINE; SWINE DISEASE; TURBINATE;

BORDETELLA BRONCHISEPTICA; MUS; SUIDAE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BORDETELLA BRONCHISEPTICA; BORDETELLA INFECTIONS; CHITOSAN; DRUG CARRIERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MICROSPHERES; RHINITIS, ATROPHIC; SWINE; SWINE DISEASES; TRANSGLUTAMINASES; TURBINATES; VIRULENCE FACTORS, BORDETELLA;

EID: 53149149493     PISSN: 10177825     EISSN: 17388872     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Aksungur, P., A. Sungur, S. Unal, A. B. Iskit, C. A. Squier, and S. Senel. 2004. Chitosan delivery systems for the treatment of oral mucositis: In vitro and in vivo studies. J. Control. Release 98: 269-279.
2. Bokor-Bratic, M. 2000. Clinical significance of analysis of immunoglobulin A levels in saliva. Med. Pregl. 53: 164-168.
3. Challacombe, S. J. 1995. Assessing mucosal humoral immunity. Clin. Exp. Immunol. 100: 181-182.
4. Chanter, N., T. Magyar, and J. M. Rutter. 1989. Interactions between Bordetella bronchiseptica and toxigenic Pasteurella multocida in atrophic rhinitis of pigs. Res. Vet. Sci. 47: 48-53.
5. Davis, S. S. 2001. Nasal vaccines. Adv. Drug Deliv. Rev. 51: 21-42.
6. de Jong, M. F. 1987. Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine. Vet. Q. 9: 123-133.
7. Donovan, M. D., G. L. Flynn, and G. L. Amidon. 1990. Absorption of polyethylene glycols 600 through 2000: The molecular weight dependence of gastrointestinal and nasal absorption. Pharm. Res. 7: 863-868.
8. Foged, N. T. 1992. Pasteurella multocida toxin. The characterization of the toxin and its significance in the diagnosis and prevention of progressive atrophic rhinitis in pigs. APMIS Suppl. 25: 1-56.
9. Francisco, C. J., T. R. Shryock, D. P. Bane, and L. Unverzagt. 1996. Serum haptoglobin concentration in growing swine after intranasal challenge with Bordetella bronchiseptica and toxigenic Pasteurella multocida type D. Can. J. Vet. Res. 60: 222-227.
10. Gatlin, C. L., W. H. Jordan, T. R. Shryock, and W. C. Smith. 1996. The quantitation of turbinate atrophy in pigs to measure the severity of induced atrophic rhinitis. Can. J. Vet. Res. 60: 121-126.
11. Gavini, E., A. B. Hegge, G. Rassu, V. Sanna, C. Testa, G. Pirisino, J. Karlsen, and P. Giunchedi. 2005. Nasal administration of carbamazepine using chitosan microspheres: In vitro/in vivo studies. Int. J. Pharm. 307: 9-15.
12. He, P., S. S. Davis, and L. Illum. 1998. In vitro evaluation of the mucoadhesive properties of chitosan microspheres. Int. J. Pharm. 166: 75-88.
13. Jacques, M., N. Parent, and B. Foiry. 1988. Adherence of Bordetella bronchiseptica and Pasteurella multocida to porcine nasal epithelial cells. Can. J. Vet. Res. 52: 283-285.
14. Jiang, H. L., I. K. Park, N. R. Shin, S. G. Kang, H. S. Yoo, S. I. Kim, S. B. Suh, T. Akaike, and C. S. Cho. 2004. In vitro study of the immune stimulating activity of an atrophic rhinitis vaccine associated to chitosan microspheres. Eur. J. Pharm. Biopharm. 58: 471-476.
15. Kang, M. L., S. G. Kang, H. L. Jiang, S. W. Shin, D. Y. Lee, J. M. Ahn, N. Rayamahji, I. K. Park, S. J. Shin, C. S. Cho and H. S. Yoo. 2006. In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur. J. Pharm. Biopharm. 63: 215-220.
16. Kang, S. W., E. R. Cho, and B. S. Kim. 2005. PLGA microspheres in hyaluronic acid gel as a potential bulking agent for urologic and dermatologic injection therapies. J. Microbiol. Biotechnol. 15: 510-518.
17. Kim, Y. H., K. Y. Cheong, W. S. Shin, S. Y. Hong, H. J. Woo, and M. S. Kwon. 2006. Immunological characterization of full and truncated recombinant clones of ompH(D:4) obtained from Pasteurella multocida (D:4) in Korea. J. Microbiol. Biotechnol. 16: 1529-1536.
18. Larsen, D. L., A. Karasin, F. Zuckermann, and C. W. Olsen. 2000. Systemic and mucosal immune responses to H1N1 influenza virus infection in pigs. Vet. Microbiol. 74: 117-131.
19. McGhee, J. R., J. Mestecky, M. T. Dertzbaugh, J. H. Eldridge, M. Hirasawa, and H. Kiyono. 1992. The mucosal immune system: From fundamental concepts to vaccine development. Vaccine 10: 75-88.
20. Mestecky, J. 1987. The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol. 7: 265-276.
21. Nakai, T., K. Kume, H. Yoshikawa, T. Oyamada, and T. Yoshikawa. 1988. Adherence of Pasteurella multocida or Bordetella bronchiseptica to the swine nasal epithelial cell in vitro. Infect. Immun. 56: 234-240.
22. Park, I. K., H. L. Jiang, C. H. Yun, Y. J. Choi, S. J. Kim, T. Akaike, S. I. Kim, and C. S. Cho. 2004. Release of Newcastle disease virus vaccine from chitosan microspheres in vitro and in vivo. Asian Austral. J. Anim. Sci. 17: 543-547.
23. Partidos, C. D. 2000. Intranasal vaccines: Forthcoming challenges. Pharm. Sci. Technolo. Today 3: 273-281.
24. Pedersen, K. B. and F. Elling. 1984. The pathogenesis of atrophic rhinitis in pigs induced by toxigenic Pasteurella multocida. J. Comp. Pathol. 94: 203-214.
25. Pereswetoff-Morath, L. 1998. Microspheres as nasal drug delivery system. Adv. Drug Deliv. Rev. 29: 185-194
26. Rutter, J. M. 1985. Atrophic rhinitis in swine. Adv. Vet. Sci. Comp. Med. 29: 239-279.
27. Sakano, T., K. Sakurai, T. Furutani, and T. Shimizu. 1984. Immunogenicity and safety of an attenuated Bordetella bronchiseptica vaccine in pigs. Am. J. Vet. Res. 45: 1814-1817.
28. Sankar, C., M. Rani, A. K. Srivastava, and B. Mishra. 2001. Chitosan based pentazocine microspheres for intranasal systemic delivery: Development and biopharmaceutical evaluation. Pharmazie 56: 223-226.
29. Sarkar, M. A. 1992. Drug metabolism in the nasal mucosa. Pharm. Res. 9: 1-9.
30. Schipper, N. G. M., J. C. Verhoef, and F. Merkus. 1991. The nasal mucociliary clearance: Relevance to nasal drug delivery. Pharm. Res. 8: 807-814.
31. Senel, S., M. J. Kremer, S. Kas, P. W. Wertz, A. A. Hincal, and C. A. Squier. 2000. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials 21: 2067-2071.
32. Shin, N. R., I. S. Choi, J. M. Kim, W. Hur, and H. S. Yoo. 2002. Effective methods for the production of immunoglobulin Y using immunogens of Bordetella bronchiseptica, Pasteurella multocida and Actinobacillus pleuropneumoniae. J. Vet. Sci. 3: 47-57.
33. To, H., S. Someno, and S. Nagai. 2005. Development of a genetically modified nontoxigenic Pasteurella multocida toxin as a candidate for use in vaccines against progressive atrophic rhinitis in pigs. Am. J. Vet. Res. 66: 113-118.
34. Ugwoke, M. I., R. U. Agu, N. Verbeke, and R. Kinget. 2005. Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives. Adv. Drug Deliv. Rev. 57: 1640-1665.
35. Varshosaz, J., H. Sadrai, and R. Alinagari. 2004. Nasal delivery of insulin using chitosan microspheres. J. Microencapsul. 21: 761-774.